GSK, iTeos
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study
Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung cancer. Shares were up 22% in premarket trading at $20.40. The stock is up more than 52% this year.
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. Shares of iTeos ...
After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...
Eva Fortea Verdejo, an analyst from Wells Fargo, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The associated ...
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...
Iteos Therapeutics said in a securities filing that it has “begun the process of transitioning from WuXi to other manufacturers.” However, the biotech noted the process “may take longer than ...
Investor's Business Daily on MSN3d
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient DeathsBiotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback